Avalyn Pharma AVLN 深 滬
等待開盤 08-21 09:30:00 美东时间
37.13
-1.840
-4.72%
華盛通- 最 高39.57
- 今 開38.65
- 成交量 17.93万股
- 最 低 36.70
- 昨 收 38.97
- 總市值 16.46亿
- 52周最高 40.17
- 市盈率 靜 --
- 換手率 0.40%
- 52周最低 24.15
- 委 比 -59.96%
- 總股本 4433.31万
- 歷史最高 40.17
- 量 比 0.95
- 振 幅 7.36%
- 歷史最低 24.15
- 每 手 1
- 風險率 3.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
Avalyn Pharma reports Q2 results
Avalyn Pharma press release (AVLN): Q2 Net loss was $28.9 million for the second quarter of 2026, as compared to $20.2 million for the second quarter of 2025. Cash Position: Cash, cash equivalents, a...
08-13 01:02
Avalyn Pharma shares are trading higher despite worse-than-expected Q2 results, likely driven by AP01 trial enrollment completion, ERS Congress abstracts, and strong cash runway into 2029 with pipeline progress.
Avalyn Pharma shares are trading higher despite worse-than-expected Q2 results, likely driven by AP01 trial enrollment completion, ERS Congress abstracts, and strong cash runway into 2029 with pipeline progress.
08-12 22:11
Avalyn Pharma Q2 EPS $(0.65) Misses $(0.53) Estimate
Avalyn Pharma (NASDAQ:AVLN) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.53) by 22.64 percent.
08-12 20:13
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Avalyn Pharma Inc. announced the completion of global enrollment for its MIST Phase 2b trial of AP01 with 398 patients, with topline data expected in late 2027. The company also reported two abstracts accepted for presentation at the European Respiratory Society Congress, focusing on AP01 lung tissue distribution and patient perspectives. As of June 30, 2026, Avalyn held $413.5 million in cash, with a cash runway projected into 2029. Recent progr...
08-12 12:00
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
Avalyn Pharma completed enrollment of 375 patients in the Phase 2b MIST trial of AP01 (inhaled pirfenidone) for progressive pulmonary fibrosis (PPF). The trial, designed to evaluate the safety and efficacy of two AP01 doses, is expected to report 12-month results in the second half of 2027. AP01 has shown promising safety and efficacy in earlier trials, with potential to improve lung function and quality of life for PPF patients.
06-17 12:00
Avalyn Pharma reports Q1 results
Avalyn Pharma press release (AVLN): Q1 net loss was $26.9 million for the first quarter of 2026, as compared to $17.5 million for the first quarter of 2025. Cash, cash equivalents, and marketable secu...
06-03 19:39
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
Avalyn Pharma announced its Q1 2026 financial results, highlighting a successful IPO with $345M gross proceeds and $123.1M in cash as of March 31, 2026. The company is advancing three inhaled therapies for pulmonary fibrosis, with AP01's Phase 2b trial on track to complete enrollment mid-2026 and AP02's Phase 2 trial underway. Recent clinical data support favorable tolerability profiles. The company expects its current cash runway to sustain oper...
06-03 11:00
美股大行评级 | 市值直指1.8万亿美元？瑞银给出美光1600美元天价目标！华尔街绩前集体上调迈威尔科技目标价
今日重点评级关注：Canaccord Genuity：维持Dakota Gold"投机性买入"评级，目标价从16美元升至18美元；瑞杰金融：上调Tectonic Therapeutic评级至"强烈买入"，目标价从76美元升至81美元
05-27 17:33
Avalyn Pharma To Present Updated Findings From ATLAS Open-Label Extension Trial Highlighting Long-Term Tolerability Profile Of AP01 For Treatment Of Pulmonary Fibrosis, At EULAR 2026
Avalyn Pharma Inc. (NASDAQ:AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced an upcoming poster
05-21 20:03
